Salivary Cancer Recruiting Phase 2 Trials for Pertuzumab (DB06366)

IndicationStatusPhase
DBCOND0080787 (Salivary Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02091141My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsTreatment